Uciane Scarlett
Principal at MPM BioImpact
Cambridge, Massachusetts
Overview
Work Experience
Principal
2021 - Current
MPM BioImpact is a biotechnology investment firm specializing in managing early-stage venture and private/public impact.
Principal
2019 - 2021
Life science investing, company creation, portfolio management Company Creation/Operations/Financing: T-Cypher Bio (interim Exec Chair), PepGen, ORFonyx, Alethiomics, Endlyz Boards: T-Cypher Bio, PepGen (NASDAQ: PEPG), Miro Bio (acq. by Gilead), Scenic Bio, DJS (acq. by AbbVie)
Associate | EIR
2018 - 2019
Life science investing, company creation, portfolio company operations. Company Creation/Board: Quench Bio, Dyne Therapeutics, Navitor Operations: Korro Bio, AVRO BIO, Quench, Dyne
Atlas Venture creates and invests in biotech startup companies with seed and early stage venture investments.
Director of Business Development & Strategy
2016 - 2018
Drove business development & corporate/pipeline strategy; participated in venture financing; conceptualized strategic academic partnership; presented to BoD; engaged with various bankers, analysts, VCs
Compass Therapeutics is a biopharmaceutical company that focuses on drugging the immune system to treat human diseases.
Raised $381,512,210.00 from Dafna Capital Management, Vivo Capital, Monashee Investment Management, Braidwell, OrbiMed, Adage Capital Management, Enavate Sciences and Janus Henderson Investors.
Manager | Consultant | Associate
2011 - 2016
Corporate/pipeline strategy, early commercial strategy, business development; strong oncology focus Drove internal initiatives geared towards growing Clarion's oncology business Published two articles (business journal & peer-reviewed journal) in oncology
Postdoctoral Fellow
2011 - 2011
The Wistar Institute is the nation’s first independent institution devoted to medical research and training.
Raised $11,599,368.00 from National Science Foundation, National Cancer Institute, US Department of Commerce, Economic Development Administation and National Institutes of Health.